One-third of adults suffer from high blood pressure and 9.4 million people a year will die from complications relating to the condition. In fact, cardiovascular disease remains the leading cause of death worldwide. Quantum Genomics is developing a new class of drugs that target an enzyme in the brain for the treatment of high blood pressure and the prevention of related cardio-vascular risks. We spoke to J.P. Milon, CEO of Quantum Genomics, about its platform technology, how it works, and why it may have promise as an approach to treating both hypertension and heart failure.
